Morphine News and Research

Latest Morphine News and Research

Two-thirds of adults support single-dose packaging to avoid accidental poisoning

Unintentional poisonings from medicines cause more emergency room visits for young children each year than do car accidents.

17 Apr 2012

AcelRx commences dosing in second ARX-01 Phase 3 clinical trial for acute post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application for the Sufentanil NanoTab PCA System, ARX-01.

12 Apr 2012

USPTO issues two Notices of Allowance to AcelRx for NanoTab formulations

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Patent and Trademark Office (USPTO) has issued AcelRx two Notices of Allowance for the patent applications entitled "Small-Volume Oral Transmucosal Dosage Forms" and "Bioadhesive Drug Formulations for Oral Transmucosal Delivery."

12 Apr 2012

QRxPharma completes MoxDuo CR Phase 1 studies on chronic pain

QRxPharma announced today successful completion of two Phase 1 studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilising a 3:2 ratio of morphine and oxycodone.

11 Apr 2012

Sucampo announces positive results from lubiprostone phase 3 trial on OBD

Sucampo Pharmaceuticals, Inc. today announced positive top-line results from an open-label phase 3 clinical trial designed to evaluate the long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction (OBD) patients with chronic, non-cancer-related pain.

6 Apr 2012

Study shows how morphine creates inflammatory response in the brain

An international team of researchers involving the University of Adelaide and University of Colorado has made a major discovery that could lead to more effective treatment of severe pain using morphine.

3 Apr 2012

TLR4/MD-2 protein complex triggers morphine-induced inflammation

A University of Colorado Boulder-led research team has discovered that two protein receptors in the central nervous system team up to respond to morphine and cause unwanted neuroinflammation, a finding with implications for improving the efficacy of the widely used painkiller while decreasing its abuse potential.

3 Apr 2012

Antidepressants can play a key role in relieving pain associated with OA

Antidepressants can play a key role in alleviating painful conditions like osteoarthritis and may result in fewer side effects than traditionally prescribed drug regimes, such as anti-inflammatories and opioids, according to a perspective paper published online ahead of print publication by the International Journal of Clinical Practice.

22 Mar 2012

Opioids may influence breast cancer survival

A new study in the April issue of Anesthesiology analyzed inherited (genetic) differences in how the body responds to its own morphine-like chemicals and pain-relieving opioid drugs, and whether they influence breast cancer survival. Preclinical animal studies have suggested that opioids may promote tumor growth.

22 Mar 2012

Acelrx fourth quarter net loss increases to $6.4 million

20 Mar 2012

QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

19 Mar 2012

AT-1001 shows promise in treating drug addiction

In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction.

15 Mar 2012

The two sides of pain

"Pain is both a curse and a blessing", says Jürgen Sandkühler, Head of the Department of Neurophysiology at the Centre for Brain Research at the MedUni Vienna ahead of the international "Brain Awareness Week", being held from the 12th to the 16th of March. On the one hand, pain has an important protective function for humans.

14 Mar 2012

Veterans prescribed more opioid pain killers: Study

According to a new government study Morphine and similar powerful painkillers are sometimes prescribed to recent war veterans suffering from post-traumatic stress along with physical pain. The study suggests that these vets are at high risk for drug and alcohol abuse, but they're two times more likely to get prescriptions for addictive painkillers than vets with only physical pain.

7 Mar 2012

AcelRx initiates ARX-01 Phase 3 study for treatment of post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported dosing of the first patient in a Phase 3 study for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia system.

6 Mar 2012

Scripps Florida study to focus on four new classes of pain-relieving compounds

Scripps Florida scientists have been awarded $3.1 million by the National Institute on Drug Abuse, part of the National Institutes of Health, to study and develop several new compounds that could prove to be effective in controlling pain without the unwanted side effects common with opiate drugs, such as morphine, Oxycontin, and Vicoden.

1 Mar 2012

News briefs from featured presentations at Cardiology 2012

Pediatric cardiology researchers and clinicians from almost 50 centers from across the U.S. and around the world are gathering at the Cardiology 2012 Conference sponsored by The Children's Hospital of Philadelphia on Feb. 22-26 in Orlando, Fla.

27 Feb 2012

Modified imatinib cancer drug prevents morphine tolerance in rats

By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.

20 Feb 2012

Trevena commences TRV130 Phase I clinical trial for severe post-operative pain

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today the initiation of a Phase I clinical trial of TRV130, a novel candidate designed for the intravenous treatment of moderate-to-severe post-operative pain.

13 Feb 2012

Medasys Prometra programmable implantable drug pump receives FDA PMA approval

Medasys Inc., a medical device company focused on providing implantable drug delivery solutions, announced today that it has received PMA approval from the U. S. Food and Drug Administration for its Prometra programmable implantable drug pump.

13 Feb 2012